{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "shortName": "CLINUVEL PHARMACEUTICALS", "messageBoardId": "finmb_6117181", "exchangeTimezoneShortName": "CEST", "market": "dr_market", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "FRA", "longName": "Clinuvel Pharmaceuticals Limited", "regularMarketChangePercent": -0.5705024, "regularMarketPrice": 12.2, "exchangeTimezoneName": "Europe/Berlin", "marketState": "REGULAR", "regularMarketChange": -0.07000065, "regularMarketTime": 1683871451, "regularMarketDayHigh": 12.2, "regularMarketDayRange": "12.2 - 12.2", "regularMarketDayLow": 12.2, "regularMarketVolume": 150, "regularMarketPreviousClose": 12.27, "bid": 12.1, "ask": 12.19, "bidSize": 800, "askSize": 800, "fullExchangeName": "Frankfurt", "financialCurrency": "AUD", "regularMarketOpen": 12.2, "averageDailyVolume3Month": 992, "averageDailyVolume10Day": 906, "fiftyTwoWeekLowChange": 3.196, "fiftyTwoWeekLowChangePercent": 0.35495338, "fiftyTwoWeekRange": "9.004 - 18.555", "fiftyTwoWeekHighChange": -6.3550005, "fiftyTwoWeekHighChangePercent": -0.3424953, "fiftyTwoWeekLow": 9.004, "fiftyTwoWeekHigh": 18.555, "trailingAnnualDividendRate": 0.04, "trailingPE": 48.8, "trailingAnnualDividendYield": 0.0032599836, "epsTrailingTwelveMonths": 0.25, "sharesOutstanding": 49410300, "bookValue": 2.817, "fiftyDayAverage": 12.2031, "fiftyDayAverageChange": -0.0031003952, "fiftyDayAverageChangePercent": -0.0002540662, "twoHundredDayAverage": 13.21675, "twoHundredDayAverageChange": -1.0167503, "twoHundredDayAverageChangePercent": -0.07692892, "marketCap": 602805632, "priceToBook": 4.3308487, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1094018400000, "priceHint": 2, "symbol": "UR9.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "535 Bourke Street", "address2": "Level 11", "city": "Melbourne", "state": "VIC", "zip": "3000", "country": "Australia", "phone": "61 3 9660 4900", "fax": "61 3 9660 4909", "website": "https://www.clinuvel.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PR\u00c9NUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA", "age": 59, "title": "CEO, MD & Director", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 2479255, "fmt": "2.48M", "longFmt": "2,479,255"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Darren M. Keamy", "age": 49, "title": "CFO & Company Sec.", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 279950, "fmt": "279.95k", "longFmt": "279,950"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dennis J. Wright", "title": "Chief Scientific Officer", "fiscalYear": 2022, "totalPay": {"raw": 221019, "fmt": "221.02k", "longFmt": "221,019"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Lachlan  Hay", "title": "Director of Global Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Malcolm  Bull", "title": "Head of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}